This case highlights a 55-year-old woman with advanced pancreatic cancer who sought a remote second opinion through Medebound HEALTH before traveling to the U.S. A video consultation with a leading MD Anderson professor clarified global treatment options, including KRAS-targeted therapies and clinical trial enrollment. The expert’s commitment to serve as her primary physician provided reassurance and direct access to cutting-edge care.

This article highlights key 2025 advances in pancreatic cancer treatment, including new FDA-approved drugs, targeted therapies, and AI-driven care. It features the real story of Mei Ling, a Stage III patient who accessed a U.S. clinical trial through Medebound HEALTH and achieved curative surgery.